Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
MNKD 
MannKind Corp (MNKD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: MNKD (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.44
1 Year Target Price $9.44
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.38% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.56B USD | Price to earnings Ratio 50.7 | 1Y Target Price 9.44 |
Price to earnings Ratio 50.7 | 1Y Target Price 9.44 | ||
Volume (30-day avg) 7 | Beta 0.81 | 52 Weeks Range 3.38 - 7.07 | Updated Date 11/13/2025 |
52 Weeks Range 3.38 - 7.07 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-11 | When - | Estimate 0.0213 | Actual 0.07 |
Profitability
Profit Margin 9.32% | Operating Margin (TTM) 22.86% |
Management Effectiveness
Return on Assets (TTM) 9.95% | Return on Equity (TTM) - |
Valuation
Trailing PE 50.7 | Forward PE 80.65 | Enterprise Value 1590216033 | Price to Sales(TTM) 5.65 |
Enterprise Value 1590216033 | Price to Sales(TTM) 5.65 | ||
Enterprise Value to Revenue 5.07 | Enterprise Value to EBITDA 21.73 | Shares Outstanding 307070281 | Shares Floating 301232875 |
Shares Outstanding 307070281 | Shares Floating 301232875 | ||
Percent Insiders 1.64 | Percent Institutions 55.15 |
Upturn AI SWOT
MannKind Corp
Company Overview
History and Background
MannKind Corporation, founded in 1991, is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutics. A significant milestone was the development and FDA approval of Afrezza, an inhaled insulin for type 1 and type 2 diabetes. The company has undergone various strategic shifts and partnerships throughout its history, with a primary focus on its innovative delivery systems.
Core Business Areas
- Inhaled Therapeutics: MannKind's core business revolves around its proprietary Technosphereu00ae dry powder inhalation technology, which is designed to deliver therapeutics to the lungs. This platform has been primarily applied to the development of insulin for diabetes management.
Leadership and Structure
MannKind Corporation is led by a management team that includes a Chief Executive Officer, Chief Financial Officer, and other key executives responsible for research and development, commercial operations, and regulatory affairs. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to scientific innovation, clinical trials, manufacturing, marketing, and sales.
Top Products and Market Share
Key Offerings
- Competitors: Novo Nordisk,Eli Lilly and Company,Sanofi
- Description: Afrezza is a rapid-acting inhaled insulin approved for adults with type 1 and type 2 diabetes. It is delivered using MannKind's Technosphereu00ae technology. As of recent reporting, specific market share data for Afrezza is not extensively disclosed by the company, but it competes in the broader diabetes market. Competitors include insulin manufacturers like Novo Nordisk (e.g., Fiasp), Eli Lilly and Company (e.g., Humalog, Lyumjev), and Sanofi (e.g., Lantus, Toujeo). The market for rapid-acting insulin is substantial.
- Market Share:
- Product Name: Afrezza
- Revenue:
- Users:
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long product development cycles, stringent regulatory processes, and significant competition. The diabetes market, in particular, is a large and growing sector driven by increasing prevalence of the disease.
Positioning
MannKind's competitive advantage lies in its proprietary Technosphereu00ae inhalation technology, which offers a unique delivery method for therapeutics. However, it faces significant competition from established pharmaceutical giants with extensive portfolios and marketing capabilities.
Total Addressable Market (TAM)
The global diabetes market is valued in the hundreds of billions of dollars, with insulin being a significant component. MannKind's position within this TAM is currently niche, particularly for its inhaled insulin product, Afrezza, compared to the broader injectable insulin market.
Upturn SWOT Analysis
Strengths
- Proprietary Technosphereu00ae inhalation technology
- FDA-approved inhaled insulin (Afrezza)
- Focus on a significant unmet medical need (diabetes)
Weaknesses
- Limited product pipeline beyond Afrezza
- Historically struggled with commercialization and market penetration
- Significant reliance on a single core product
- Financial challenges and need for ongoing funding
Opportunities
- Expansion of Afrezza's indications or patient populations
- Licensing or partnering opportunities for the Technosphereu00ae platform in other therapeutic areas
- Growth in the global diabetes market
- Potential for new drug development using the inhalation technology
Threats
- Intense competition from established pharmaceutical companies
- Regulatory hurdles for new product approvals
- Pricing pressures in the pharmaceutical market
- Challenges in patient and physician adoption of new delivery methods
- Potential for alternative diabetes treatments
Competitors and Market Share
Key Competitors
- Novo Nordisk (NVO)
- Eli Lilly and Company (LLY)
- Sanofi (SNY)
Competitive Landscape
MannKind's competitive landscape is dominated by large, well-established pharmaceutical companies with extensive resources, established distribution channels, and broad product portfolios in the diabetes market. MannKind's advantage is its unique delivery technology, but it faces challenges in matching the scale and reach of its competitors.
Growth Trajectory and Initiatives
Historical Growth: MannKind's historical growth has been closely tied to the development and commercialization efforts for Afrezza. Growth has been challenging due to market penetration and competition.
Future Projections: Future growth projections are contingent on increasing Afrezza sales, potential new partnerships, and the successful development of any pipeline assets. Analyst estimates would provide specific forward-looking revenue and EPS projections.
Recent Initiatives: Recent initiatives likely focus on expanding Afrezza's market presence, optimizing manufacturing and supply chains, and exploring strategic collaborations to leverage their technology platform.
Summary
MannKind Corporation possesses a novel inhalation technology with its key product, Afrezza, addressing a significant market. However, the company has faced persistent challenges in commercializing its product and achieving widespread market adoption against formidable competitors. Its future success hinges on accelerating Afrezza's growth and potentially leveraging its technology platform through strategic partnerships to overcome financial and market penetration hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations reports
- Financial news outlets
- Pharmaceutical industry analysis reports
- Market research data
Disclaimers:
This JSON output is generated based on publicly available information and analysis. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data and specific financial figures can fluctuate and may require real-time access to proprietary databases for precise up-to-the-minute accuracy. Competitors and their market share can change over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MannKind Corp
Exchange NASDAQ | Headquaters Danbury, CT, United States | ||
IPO Launch date 2004-07-28 | CEO & Director Dr. Michael E. Castagna Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.mannkindcorp.com |
Full time employees 403 | Website https://www.mannkindcorp.com | ||
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.